pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
908
stories
4h
STAT+: HHS document offers new clues to Kennedy’s vaccine plans
stat
6h
Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths
biospace
6h
Werewolf and Ambros to tie the knot in $150M rare disease deal
biospace
7h
STAT+: Up and down the ladder: The latest comings and goings
stat
7h
STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
stat
7h
STAT+: Are cancer patients getting too much drug?
stat
7h
Scientists deploy Merck’s Ebola vaccine in DRC
stat
7h
As Trump 2.0 targets federal research, a new study shows the stakes
endpoints
12h
Opinion: A cure for HIV would be a triumph. But it shouldn’t harm survivors
stat
12h
Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?
stat
1d
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
1d
Cancer vaccine win restores Wall Street’s faith in Moderna
biopharma dive
1d
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
1d
STAT+: FDA approves Ultragenyx gene therapy
stat
1d
Contrasting legal decisions on gender-affirming care
stat
1d
STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
stat
1d
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
1d
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
1d
STAT+: One of the most consequential years for cancer treatment, ever
stat
1d
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
1d
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
fiercebiotech
1d
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
1d
STAT+: How health systems are embracing chatbots to query and summarize patient records
stat
1d
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
2d
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
2d
For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars
endpoints
2d
Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy
fiercebiotech
2d
STAT+: Experts scrutinize Huidagene’s disclosures after patient death
stat
2d
STAT+: Regeneron drug for disease that causes dangerous bone growth earns FDA approval
stat
2d
Trump nominates policy aide Overton to lead FDA
biopharma dive
← prev
page 1 of 31
next →
